Cencora, Inc. (COR) Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
Cencora, Inc. (COR), headquartered in Conshohocken, is a leading healthcare distribution company specializing in the sourcing and distribution of pharmaceutical products. Known for its robust U.S. Healthcare Solutions segment, Cencora serves key clients including acute care hospitals, retail pharmacies, and medical clinics, providing essential services such as pharmacy management and clinical trial support. Additionally, the International Healthcare Solutions segment caters to the biopharmaceutical sector in Europe with pharmaceutical wholesale services and logistics. Established in 1985 as AmerisourceBergen Corporation, Cencora has built a solid reputation in medical distribution, positioning itself as an attractive investment within the expanding healthcare industry. The company’s total revenue stands at approximately $283.83 billion, reflecting a strong financial foundation and growth potential, emphasizing a positive outlook for potential investors.
Investment Outlook
Cencora’s current stock price is $228.11, with a promising target high price of $284.00, representing an upside potential of about 24.5%. Analysts have projected a mean target price of $261.12, further indicating favorable growth prospects. The stock has a total of 196,008,000 shares outstanding, with 9,516,722 shares short, constituting approximately 6.59% of the float. This moderate short interest suggests a generally bullish sentiment among investors, despite some speculation against its performance. Given the sustained demand for healthcare products and solutions, the recommendation for Cencora is to “buy,” underscoring confidence in the company’s potential to capitalize on the growing market needs.
Performance Summary
Cencora’s stock is currently trading below the fifty-day moving average of $234.51 and the fifty-two-week high of $247.66, indicating a weaker momentum as it approaches its fifty-two-week low of $178.21. This performance fluctuation reveals potential challenges or market corrections, which investors should carefully evaluate when forming investment strategies. Critical price levels identified in this analysis will serve as important indicators of support or resistance in the near term. With a mean analyst recommendation score of 2.2 derived from 15 opinions, there appears to be a consensus favoring Cencora’s growth outlook, solidifying its standing as a desirable investment in the healthcare sector.
| Metric | Value |
|---|---|
| Market Cap | $44.7b |
| Total Debt | $6.1b |
| Total Cash | $3.3b |
| Shares Outstanding | 196.0m |
| Float Shares | 176.2m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.